Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
DAREON-7
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
- NCT06132113 ↗
- Active, not recruiting
- Boehringer Ingelheim
- Standard
We haven't built an HCP commentary report on DAREON-7 (BI 764532, carboplatin and 2 more in Neuroendocrine Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DAREON-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Neuroendocrine Neoplasms
- Interventions
- BI 764532; Carboplatin; Etoposide; Cisplatin
- Arms
- Part A1: BI 764532 low dose + carboplatin + etoposide · Experimental
- Part A1: BI 764532 medium dose + carboplatin + etoposide · Experimental
- Part A1: BI 764532 high dose + carboplatin + etoposide · Experimental
- Part B: BI 764532 + carboplatin + etoposide · Experimental
- Part B: BI 764532 + cisplatin + etoposide · Experimental
- Part A2: BI 764532 + carboplatin + etoposide · Experimental
- Enrollment
- 65
- Primary outcomes
- Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
- Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
- Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment period
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 22, 2024
- Primary completion
- Oct 9, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06132113 · updated Oct 6, 2026